37 results on '"Stewart, Paul"'
Search Results
2. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy
3. Extensive experience in the management of macroprolactinomas
4. Saving lives of patients with adrenal insufficiency: a pan-European initiative?
5. Evaluating tertiary adrenal insufficiency in rheumatology patients on long‐term systemic glucocorticoid treatment
6. A comparative quality assessment of evidence-based clinical guidelines in endocrinology
7. Is there sufficient evidence to consider the use of 11β-hydroxysteroid dehydrogenase type 1 inhibition in children?
8. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease
9. Adrenal vein sampling for Primary Aldosteronism: time for a reality check
10. Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis
11. Induction of hepatic 11β-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease
12. Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome
13. Assessing the HPA axis in patients with pituitary disease: a UK survey
14. Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study
15. Efficacy of Sandostatin® LAR® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy
16. Possible association but no linkage of the HSD11B2 gene encoding the kidney isozyme of 11β-hydroxysteroid dehydrogenase to hypertension in Black people
17. Carbenoxolone effects in congenital adrenal hyperplasia
18. The short Synacthen test: is less best?*
19. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR®)
20. Increased central adiposity and decreased subcutaneous adipose tissue 11β‐hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose tolerance—A longitudinal cohort study
21. Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy
22. 'The fat lady sings', but what is she telling us?
23. Long-term therapy with long-acting octreotide (Sandostatin-LAR®) for the management of acromegaly
24. Comparison of the short ACTH stimulation test with the insulin tolerance/glucagon test
25. Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man
26. 11β-Hydroxysteroid dehydrogenase: implications for clinical medicine
27. Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer
28. Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy.
29. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy
30. Assessing the HPA axis in patients with pituitary disease: a UK survey
31. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism
32. Mineralocorticoid hypertension and congenital deficiency of 11β‐hydroxysteroid dehydrogenase in a family with the syndrome of‘apparent’mineralocorticoid excess
33. Deficient inactivation of cortisol by 11β‐hydroxysteroid dehydrogenase in essential hypertension
34. Reproduction and the shuttle
35. Mineralocorticoid excess and inhibition of 11 β‐hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome
36. Efficacy of Sandostatin® LAR® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy.
37. Long-term therapy with long-acting octreotide (Sandostatin-LAR[sup ®]) for the management of acromegaly.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.